JP2024542523A - 神経変性障害の治療選択及び治療 - Google Patents

神経変性障害の治療選択及び治療 Download PDF

Info

Publication number
JP2024542523A
JP2024542523A JP2024530556A JP2024530556A JP2024542523A JP 2024542523 A JP2024542523 A JP 2024542523A JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024542523 A JP2024542523 A JP 2024542523A
Authority
JP
Japan
Prior art keywords
weeks
disease
gene
subject
disorder associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024530556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542523A5 (cg-RX-API-DMAC10.html
Inventor
ミスリング、クリストファー、ユー.
Original Assignee
アナベックス ライフ サイエンス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アナベックス ライフ サイエンス コーポレイション filed Critical アナベックス ライフ サイエンス コーポレイション
Publication of JP2024542523A publication Critical patent/JP2024542523A/ja
Publication of JP2024542523A5 publication Critical patent/JP2024542523A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2024530556A 2021-11-23 2022-11-23 神経変性障害の治療選択及び治療 Pending JP2024542523A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163282615P 2021-11-23 2021-11-23
US63/282,615 2021-11-23
US202263393573P 2022-07-29 2022-07-29
US63/393,573 2022-07-29
PCT/US2022/050940 WO2023097029A1 (en) 2021-11-23 2022-11-23 Therapy selection and treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2024542523A true JP2024542523A (ja) 2024-11-15
JP2024542523A5 JP2024542523A5 (cg-RX-API-DMAC10.html) 2025-12-03

Family

ID=86540341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530556A Pending JP2024542523A (ja) 2021-11-23 2022-11-23 神経変性障害の治療選択及び治療

Country Status (6)

Country Link
US (1) US20240417798A1 (cg-RX-API-DMAC10.html)
EP (1) EP4436573A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024542523A (cg-RX-API-DMAC10.html)
AU (1) AU2022396274A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237579A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023097029A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122374019A (zh) * 2023-09-08 2026-07-10 阿纳韦克斯生命科学公司 脑萎缩的治疗和预防
WO2025117826A1 (en) * 2023-11-30 2025-06-05 Anavex Life Sciences Corp. Methods of using surrogate biomarkers in sigma-1 receptor therapy
CN117679516A (zh) * 2023-12-13 2024-03-12 广东工业大学 Ndufa7基因在制备改善和/或治疗线粒体功能障碍相关疾病的药物中的应用
WO2025231180A1 (en) * 2024-05-01 2025-11-06 Anavex Life Sciences Corp. Blarcamesine correction of eeg biomarkers in fragile x syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476103B1 (en) * 2005-10-17 2009-01-13 Penelope Anne Norman Science party kit and method
CN106501251A (zh) * 2016-12-09 2017-03-15 防城港市质量技术监督局 一种用于检测大麻油的试剂盒
US20200338045A1 (en) * 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US12383526B2 (en) * 2018-05-18 2025-08-12 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
WO2020018461A1 (en) * 2018-07-16 2020-01-23 The University Of Virginia Patent Foundation Compositions and methods of diagnosis and treatment for neurological diseases

Also Published As

Publication number Publication date
US20240417798A1 (en) 2024-12-19
EP4436573A1 (en) 2024-10-02
WO2023097029A1 (en) 2023-06-01
CA3237579A1 (en) 2023-06-01
AU2022396274A1 (en) 2024-05-23
EP4436573A4 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
US20240417798A1 (en) Therapy selection and treatment of neurodegenerative disorders
WO2016179097A1 (en) Methods for treating mitochondrial damage diseases
JP2022514194A (ja) 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
CN109803647A (zh) α-丁酮酸、α-酮戊二酸和2-羟基丁酸用于刺激毛发生长
JP2022009066A (ja) S-エコールを用いてアルツハイマー病を診断するおよび治療する方法
JP2025501646A (ja) Gm2ガングリオシドーシスの処置
JP2009528028A (ja) 哺乳類における健康状態を促進するためのレスベラトロールおよびその誘導体の使用
KR102527378B1 (ko) 2'-fl을 함유하는 도파민 감소로 말미암아 발생하는 질환의 개선, 예방 또는 치료용 조성물
US20240131038A1 (en) Anti-inflammatory compositions comprising cannabidiol, delta-9-tetrahydrocannabinol and linalool
JPWO2008056452A1 (ja) 希少糖の筋萎縮性側索硬化症と関連した運動障害の発症または進行の遅延への利用
EP4591861A1 (en) Use of 4-tmap for treating or relieving depression
JP7744419B2 (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
EP4562184A2 (en) Therapy selection and treatment of neurodegenerative disorders
CN118613282A (zh) 神经退行性病症的疗法选择和治疗
CN108078984B (zh) 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用
WO2023192372A1 (en) Methods of treating sjögren-larssen syndrome
WO2022165348A1 (en) Methods and compositions for preventing or reducing neuroinflammation
WO2025117826A1 (en) Methods of using surrogate biomarkers in sigma-1 receptor therapy
WO2021245658A1 (en) Compositions and methods for treating headaches
CN105748460B (zh) 一种治疗老年痴呆的药物
WO2020188569A1 (en) Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
WO2025231180A9 (en) Blarcamesine correction of eeg biomarkers in fragile x syndrome
WO2025264845A1 (en) Use of anavex3-71 for medical treatments
KR20190121569A (ko) 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251125